仅用于工业应用或科学研究，不可用于人类或动物的临床诊断或治疗，非药用. Refanezumab （GSK249320） is an IgG1-type humanized monoclonal antibody directed against myelin-associated glycoprotein （MAG）. Refanezumab binds to MAG and blocks MAG-mediated inhibition of axonal regeneration. Refanezumab can cross the blood-brain barrier （BBB） in animal stroke models. Refanezumab has the potential for the enhancement of recovery of function poststroke